Dear LabPulse reader,
This week, changes in corporate structure were at the forefront of the news, with Gilead announcing layoffs in three locations and a facility closure. Meanwhile, Labcorp announced its acquisition of the molecular testing site and other assets of Lab Works; the firm also announced the retirement of chief financial officer (CFO) Glenn Eisenberg and welcomed its new CFO, Julia Wang.
Innovative work in screening was also an important topic this week: Researchers at the U.S. National Institutes of Health (NIH) shared findings from a clinical trial matching system they developed called TrialGPT showing that the large language models-driven system could speed up screening time by 42.6%. Revvity, the firm formerly known as PerkinElmer, announced that it will be expanding its work with Genomics England involving whole genomic sequencing newborn screening for over 200 rare genetic conditions as part of the Generation Study in England's National Health Service hospitals.
Rounding out our top news for the week, Roche announced that its Ventana FOLR1 RxDx companion diagnostic assay, designed to help identify ovarian cancer patients who may be eligible for treatment with antibody-drug conjugate therapy Elahere, has received the CE Mark under the European Union's In Vitro Diagnostic Regulation.
Thanks for reading our newsletter.
